Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?
Gains in event-free and overall survival from the KEYNOTE-522 trial have incorporated pembrolizumab into the neoadjuvant and adjuvant armamentarium for stage II-III triple-negative breast cancer (TNBC). However, the lack of a second randomization to pembrolizumab after surgery raises the question of whether the adjuvan...